Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)

被引：0

作者：

Yang Yang

Li Zhu

Yan Cheng

Zhichao Liu

Xiaoyue Cai

Jinchen Shao

Ming Zhang

Jun Liu

Yifeng Sun

Yin Li

Jun Yi

Bentong Yu

Hongjing Jiang

Hezhong Chen

Hong Yang

Lijie Tan

Zhigang Li

机构：

[1] Shanghai Chest Hospital,Department of Thoracic Surgery

[2] Shanghai Jiao Tong University,Department of Radiology

[3] Shanghai Chest Hospital,Department of Radiation Oncology

[4] Shanghai Jiao Tong University,Department of Integrative Medicine

[5] Shanghai Chest Hospital,Department of Pathology

[6] Shanghai Jiao Tong University,Department of Thoracic Surgery

[7] Shanghai Chest Hospital,Department of Cardiothoracic Surgery

[8] Shanghai Jiao Tong University,Department of Thoracic Surgery

[9] Shanghai Chest Hospital,Department of Thoracic Surgery

[10] Shanghai Jiao Tong University,Department of Thoracic Surgery

[11] Cancer Hospital Chinese Academy of Medical Sciences,Department of Thoracic Surgery

[12] Jinling Hospital,Department of Thoracic Surgery

[13] Medical School of Nanjing University,undefined

[14] The First Affiliated Hospital of Nanchang University,undefined

[15] Tianjin Medical University Cancer Hospital,undefined

[16] Changhai Hospital Affiliated to The Second Military Medical University,undefined

[17] Sun Yat-Sen University Cancer Center,undefined

[18] Zhongshan Hospital Affiliated to Fudan University,undefined

来源：

BMC Cancer | / 22卷

关键词：

Esophageal cancer; Camrelizumab; Chemoradiotherapy; Chemotherapy; Clinical trial;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 168 条

[1]

Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2]

Ferlay J(2021)The Landmark Series: Multimodal Therapy for Esophageal Cancer Ann Surg Oncol 28 3375-3382

[3]

Siegel RL(2012)Preoperative chemoradiotherapy for esophageal or junctional cancer N Engl J Med 366 2074-2084

[4]

Laversanne M(2015)Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial Lancet Oncol 16 1090-1098

[5]

Soerjomataram I(2021)Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Lancet 398 759-771

[6]

Jemal A(2022)Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma N Engl J Med 386 449-462

[7]

Bray F(2021)Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial JAMA 326 916-925

[8]

Demarest CT(2020)The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma J Thorac Dis 12 6426-6434

[9]

Chang AC(2021)Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT) Clin Cancer Res 27 3351-3359

[10]

van Hagen P(2021)Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1) Eur J Cancer 144 232-241

← 1 2 3 4 5 6 7 8 9 10 →